Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study.

ABSTRACT:

Background

Type 2 diabetes mellitus (T2DM) and gout are associated with an increased risk of cardiovascular events. Despite the approval for the secondary prevention of cardiovascular diseases by the United States Food and Drug Administration in 2023, evidence regarding the effectiveness of colchicine among T2DM population remains limited.

Objectives

We aimed to evaluate the association between the use of colchicine and the risk of major adverse cardiovascular events (MACE) among patients with gout and T2DM.

Methods

We conducted a nationwide, population-based cohort study with active comparator, new-user design using nationwide claims data of South Korea (2010-2022). Patients with T2DM and gout who initiated colchicine or non-steroidal anti-inflammatory drugs (NSAIDs)

SUBMITTER: Jeon M 

PROVIDER: S-EPMC12617512 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature